【导读】NLRP3介导的炎症反应在先天免疫功能中起着至关重要的作用，但NLRP3炎性小体在调节酒精性肝病（ALD）肠稳态和肠道上皮屏障方面的作用尚不 ...

Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...

Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, ...

and atherosclerosis. The NLRP3 inflammasome is activated by diverse stimuli, and multiple molecular and cellular events, including ionic flux, mitochondrial dysfunction, and the production of ...

Once again, NASH was trumpeted as the primary focus of that deal, along with gout and atherosclerosis. Other companies active in the NLRP3 category include NodThera, which has a lead candidate ...

"What's become apparent over recent years is that one inflammasome in particular – the NLRP3 inflammasome – is very important in a number of major diseases such as obesity and atherosclerosis ...

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...

Activation of the NLRP3 inflammasome, and resulting chronic inflammation, has been linked to a range of cardiometabolic diseases including atherosclerosis, insulin resistance, and obesity.

Topline results are expected in the second half of 2025. Activation of the NLRP3 inflammasome, and resulting chronic inflammation, has been linked to a range of cardiometabolic diseases including ...